ATE525908T1 - Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen - Google Patents

Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen

Info

Publication number
ATE525908T1
ATE525908T1 AT03808435T AT03808435T ATE525908T1 AT E525908 T1 ATE525908 T1 AT E525908T1 AT 03808435 T AT03808435 T AT 03808435T AT 03808435 T AT03808435 T AT 03808435T AT E525908 T1 ATE525908 T1 AT E525908T1
Authority
AT
Austria
Prior art keywords
antigen
cells
cd1a
surface markers
loaded
Prior art date
Application number
AT03808435T
Other languages
English (en)
Inventor
Jacques Banchereau
Anna K Palucka
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Application granted granted Critical
Publication of ATE525908T1 publication Critical patent/ATE525908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03808435T 2002-12-04 2003-12-04 Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen ATE525908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43079102P 2002-12-04 2002-12-04
PCT/US2003/038553 WO2004050855A2 (en) 2002-12-04 2003-12-04 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Publications (1)

Publication Number Publication Date
ATE525908T1 true ATE525908T1 (de) 2011-10-15

Family

ID=32469531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03808435T ATE525908T1 (de) 2002-12-04 2003-12-04 Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen

Country Status (7)

Country Link
US (1) US20060239962A1 (de)
EP (2) EP2301356A3 (de)
JP (3) JP4662776B2 (de)
CN (1) CN100337686C (de)
AT (1) ATE525908T1 (de)
AU (1) AU2003302504B2 (de)
WO (1) WO2004050855A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056977B (zh) * 2004-10-04 2013-01-30 拜欧瓦克西姆有限公司 用于治疗hiv感染患者的亚型匹配的灭活全病毒疫苗
CN101080487B (zh) 2004-10-07 2012-11-14 阿戈斯治疗公司 成熟树突细胞组合物及其培养方法
CN101155914B (zh) * 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
US7919265B2 (en) * 2006-06-21 2011-04-05 Children's Research Institute Antibody-based method for isolating Th1 and Th2 helper lymphocytes from human peripheral blood
US20090011458A1 (en) * 2007-06-19 2009-01-08 Johnson Paul E Method for selectively staining microorganisms
CL2007002825A1 (es) * 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
KR20210120136A (ko) * 2009-12-04 2021-10-06 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 배아줄기세포 유래된 혈액모세포로부터 자연 살해 세포 및 수지상 세포를 생성하는 방법
US20130129713A1 (en) 2010-08-04 2013-05-23 Ieo - Istituto Europeo Di Oncologia S.R.L. Method of antigen loading for immunotherapy
WO2013167156A1 (en) * 2012-05-11 2013-11-14 Otto-Von-Guericke-Universität Magdeburg Transplantation of modified monocytes
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
CN105802908B (zh) * 2014-12-29 2020-06-23 复旦大学附属肿瘤医院 一种体外制备肿瘤抗原特异性cd8+干细胞样记忆性t淋巴细胞的方法
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3167898A1 (de) 2015-11-11 2017-05-17 IEO - Istituto Europeo di Oncologia Srl Verfahren zur gewinnung von tumorpeptiden und verwendungen davon
CN107541498A (zh) * 2016-06-27 2018-01-05 复旦大学附属肿瘤医院 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途
EP3876977A1 (de) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimäre antigen-rezeptoren für phagocytose
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JP2022546592A (ja) 2019-09-03 2022-11-04 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP6782503B1 (ja) * 2019-12-12 2020-11-11 康基 土方 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
CN112458058B (zh) * 2020-11-24 2023-09-01 康九生物科技(长春)有限公司 一种过表达traf6的dc细胞、dc细胞疫苗及构建方法和应用
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CN114686431B (zh) * 2022-03-30 2023-09-15 益诺思生物技术南通有限公司 一种免疫毒性的评价方法及模型
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
JP3840268B2 (ja) * 1997-07-15 2006-11-01 タカラバイオ株式会社 細胞傷害性ｔリンパ球
ES2217585T3 (es) * 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
WO2001021653A2 (en) * 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1299523B1 (de) * 2000-07-10 2008-12-24 Eppendorf Ag Verfahren zur modifizierung von biologischen zellen
EP1390064A4 (de) 2001-03-09 2006-10-18 Baylor Res Inst Verfahren zur behandlung von bösartigen erkrankungen durch auslösung von blutimmunantworten

Also Published As

Publication number Publication date
AU2003302504A1 (en) 2004-06-23
WO2004050855A2 (en) 2004-06-17
JP2013224313A (ja) 2013-10-31
EP2301356A2 (de) 2011-03-30
EP1567014A4 (de) 2006-02-01
JP2006508664A (ja) 2006-03-16
JP2011046717A (ja) 2011-03-10
JP4662776B2 (ja) 2011-03-30
JP5919226B2 (ja) 2016-05-18
CN1744822A (zh) 2006-03-08
US20060239962A1 (en) 2006-10-26
JP5498333B2 (ja) 2014-05-21
WO2004050855A3 (en) 2005-02-03
CN100337686C (zh) 2007-09-19
AU2003302504B2 (en) 2007-03-08
EP1567014A2 (de) 2005-08-31
EP1567014B1 (de) 2011-09-28
EP2301356A3 (de) 2012-05-30

Similar Documents

Publication Publication Date Title
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
KR101327297B1 (ko) 유기무기 복합체 분산액 및 그것을 사용하여 제조되는 세포 배양 기재, 및 그들의 제조 방법
JP2013512694A5 (de)
WO2004076651A3 (en) Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
MX2008007286A (es) Ingenieria in vivo de superficie celular.
PL351893A1 (en) Vaccines
WO2009117616A3 (en) Carbon nanotube compositions and methods of use thereof
CA2291065A1 (en) Raf kinase inhibitors
ZA200301466B (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells.
JP2013177430A5 (de)
WO2001054716A3 (en) Genetically engineered tumor cell vaccines
CA2354046A1 (en) New cancer treatments
PL1664319T3 (pl) Sposób wytwarzania polisacharydu otoczkowego do zastosowania w szczepionkach koniugatowych
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
DE19602985A1 (de) Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
Liu et al. Ca2+-mediated surface polydopamine engineering to program dendritic cell maturation
SI1530628T1 (sl) Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
Maia et al. In vitro evaluation of acellular dermal matrix as a three‐dimensional scaffold for gingival fibroblasts seeding
ATE485356T1 (de) Verfahren zur herstellung von zellförmigen kohleprodukten
Liu et al. Periodic arrangement of lipopolysaccharides nanostructures accelerates and enhances the maturation processes of dendritic cells
JP2020535832A5 (de)
Nagareddy et al. Stimuli-responsive polymeric nanomaterials for the delivery of immunotherapy moieties: antigens, adjuvants and agonists
JP2011526923A5 (de)
Ma et al. A near-infrared light-driven Janus nanomotor for deep tumor penetration and enhanced tumor immunotherapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties